Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks hidden blood sugar index fluctuations in diabetes patients

NCT ID NCT06185491

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how a measure called the hemoglobin glycation index (HGI) changes over time in 750 adults with diabetes who use continuous glucose monitors. HGI compares lab-measured blood sugar levels with estimated levels from a glucose monitor. Researchers will collect data three times over about 18 months to see how stable this index is. The goal is to better understand blood sugar patterns, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

750 people

The number who actually took part.

Started

Jun 2024

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Major (adult subject over 18), with no upper age limit * Enrolled in a social security scheme or beneficiary of such a scheme * Agreement to participate (informed, written consent) * Established diabetes (regardless the type of diabetes), known for at least 6 months at inclusion * Regular user of a glucose monitoring system for at least 3 months. Non inclusion Criteria: * Known hemoglobinopathy * Inadequate use of the flash glucose monitoring system with a capture rate of less than 70% of interstitial glucose measurements, during the 3 months preceding the inclusion visit. * Stage 5 renal insufficiency (CKD-EPI less than 15 mL/min/1.73 m2) * Pregnant or breast-feeding * Major under guardianship, curatorship or safeguard of justice * Any situation assessed by the investigator as potentially prejudicial to the participant's health as a result of participation in the study Exclusion criteria: * Treatment with corticosteroids in the 3 months preceding the visit * Unusual acute situation (infection, very unusual physical activity, etc.) deemed significant by the investigator * Pregnancy started

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus

Contacts and locations

Locations

  • CH du Mans

    Le Mans, 72037, France

  • CHU d'Angers

    Angers, 49100, France

  • CHU de Brest

    Brest, 29200, France

  • CHU de Caen

    Caen, 14033, France

  • CHU de Nantes

    Nantes, 44093, France

  • CHU de Poitiers

    Poitiers, 86021, France

  • CHU de Rennes

    Rennes, 35000, France

  • CHU de Toulouse

    Toulouse, 31059, France

  • Hôpital NOVO

    Pontoise, 95300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.